Primary small-cell neuroendocrine carcinoma of the bladder: Case report and literature review


Submitted: December 29, 2019
Accepted: March 27, 2020
Published: October 2, 2020
Abstract Views: 2633
PDF: 1453
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Valerio Olivieri Division of Urology, Ivrea Hospital (ASL TO4), Ivrea (Turin), Italy.
  • Valentina Fortunati Division of Pathology, Hospital Policlinico of Tor Vergata, Rome, Italy.
  • Luca Bellei Division of Urology, Ivrea Hospital (ASL TO4), Ivrea (Turin), Italy.
  • Massimo Massarelli Division of Urology, Ivrea Hospital (ASL TO4), Ivrea (Turin), Italy.
  • Gabriele Ruggiero Division of Urology, Ciriè Hospital (ASLTO4), Ciriè (Turin), Italy.
  • Danilo Abate Division of Urology, Ciriè Hospital (ASLTO4), Ciriè (Turin), Italy.
  • Nicoletta Serra Division of Urology, Ciriè Hospital (ASLTO4), Ciriè (Turin), Italy.
  • Daniele Griffa Division of Urology, Ivrea Hospital (ASL TO4), Ivrea (Turin); Division of Urology, Ciriè Hospital (ASLTO4), Ciriè (Turin), Italy.
  • Flavio Forte Division of Urology, Hospital “Madre Giuseppina Vannini”, Rome, Italy.
  • Emanuele Corongiu Division of Urology, Hospital “Madre Giuseppina Vannini”, Rome, Italy.

Background: Neuroendocrine tumours (NET) are extremely rare and aggressive. Although they commonly affect intestine, many organs may be involved such as pancreas, lung or urinary tract. Bladder is rarely involved. Actually, two main forms of bladder NET have been described: small-cell and large-cell. The first one is considered highly agressive since it shows poor oncologic outcomes being mainly diagnosed at advanced stage: the second one is extremely rare and equally aggressive.
Case report: A 78-years-old Caucasian male presented to our facility for lower urinary tract symptoms and gross hematuria recently occurred. He was a strong smoker since many years. No familiarity for urothelial cancer was referred nor previous episodes of hematuria until that time. Citology was negative; outpatient ultrasound of the bladder revealed a 3 cm bladder thickening highly suspicious for bladder cancer; patient underwent TC scan that confirmed the bladder lesion. A transurethral resection of the bladder (TURB) was performed. After 3 months total body TC showed multiple visceral metastases also involving brain and lymph nodes. Best supportive care was offered but the patient died 6 months later.
Results: Pathology revealed a mixed bladder tumor: 30% of the specimen resulted as an high-grade urothelial cancer (G3) and 70% as small-cell neuroendocrine variant.Microscopic muscle involvement was excluded.
Conclusions: Neuroendocrine tumors are uncommon entities which origin from cells of neuro-endocrine system and may potentially involve all human tissues. Neuroendocrine smallcell carcinoma of the bladder is a non-urothelial histotype: it is highly aggressive and diagnosed mainly at advanced stages. Whenever considering the high risk of metastatic spread and the poor prognosis, a multimodal approach is highly suggested. TURB alone is uneffective in disease control due to its aggressive nature. Unless metastatic, radical cystectomy and adjuvant chemotherapy represent the gold standard.


Al-Ahmadie H., Iyer G. Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants. Surg Pathol Clin. 2018 Dec; 11(4):713-723 DOI: https://doi.org/10.1016/j.path.2018.07.011

Cramer SF., Aikawa M., Cebelin M. Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer. 1981; 47(4):724-30 DOI: https://doi.org/10.1002/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2

Siefker-Radtke AO., Dinney CP., Abrahams NA., Moran C., Shen Y., Pisters LL. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172;481-484 DOI: https://doi.org/10.1097/01.ju.0000132413.85866.fc

Olivieri, V., Fortunati, V., Bellei, L., Massarelli, M., Ruggiero, G., Abate, D., Serra, N., Griffa, D., Forte, F., & Corongiu, E. (2020). Primary small-cell neuroendocrine carcinoma of the bladder: Case report and literature review. Archivio Italiano Di Urologia E Andrologia, 92(3). https://doi.org/10.4081/aiua.2020.3.211

Downloads

Download data is not yet available.

Citations